KZR VS TCRR Stock Comparison

Performance

KZR
10/100

KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

TCRR
10/100

TCRR returned -33.76% in the last 12 months. Based on the other stocks in its sector with an average return of -7.44%, its performance is below average giving it a grade of 10 of 100.

Analyst Price Targets

KZR
94/100

4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.

TCRR

"Analyst Price Targets" not found for TCRR

Sentiment

KZR
71/100

KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.

TCRR
68/100

TCRR had a bullish sentiment score of 67.81% across Twitter and StockTwits over the last 12 months. It had an average of 4.79 posts, 0.39 comments, and 0.64 likes per day.

Technicals

KZR
29/100

KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

TCRR
21/100

TCRR receives a 21 of 100 based on 14 indicators. 3 are bullish, 11 are bearish.

Earnings

KZR
10/100

KZR has missed earnings 6 times in the last 20 quarters.

TCRR
10/100

TCRR has missed earnings 12 times in the last 20 quarters.

Profit

KZR
10/100

Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

TCRR
10/100

Out of the last 13 quarters, TCRR has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

KZR
41/100

KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

TCRR
48/100

TCRR has had a lower than average amount of volatility over the last 12 months giving it a grade of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Kezar Life Sciences, Inc. Common Stock Summary

Nasdaq / KZR

Healthcare

Biotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

TCR2 Therapeutics Inc. Common Stock Summary

Nasdaq / TCRR

Healthcare

Biotechnology

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio